论文部分内容阅读
目的探讨宫颈癌新辅助化疗后手术切除组织病理学变化。方法收集2008年3月至2012年3月期间在我院接受治疗的宫颈癌患者50例,全部在手术切除之前予以新辅助化疗(NACT),并在化疗前后予以c-erbB-2、p53、nm23、VEGF免疫组化检测,观察50例组患者新辅助化疗和手术切除的临床效果,探讨治疗后患者的组织形态学变化情况以及免疫组化检查结果。结果经过新辅助化疗,大部分患者的病情得到缓解,患者的c-erbB-2、p53、nm23无显著变化,VEGF明显改善,并且患者的手术切除效果良好。结论新辅助化疗对宫颈癌患者具有良好的临床应用效果,加上及时的手术治疗,肿瘤切除率能够显著升高。
Objective To investigate the histopathological changes of surgical resection after neoadjuvant chemotherapy for cervical cancer. Methods Fifty patients with cervical cancer treated in our hospital from March 2008 to March 2012 were enrolled in this study. All of them were treated with neoadjuvant chemotherapy (NACT) before surgery and c-erbB-2, p53, nm23, VEGF immunohistochemical detection of 50 cases of patients with neoadjuvant chemotherapy and surgical resection of the clinical effect of the treatment of patients with histological changes and immunohistochemistry results. Results After neoadjuvant chemotherapy, the majority of patients were relieved of the disease. There was no significant change in c-erbB-2, p53, nm23, VEGF was significantly improved, and the surgical resection effect was good. Conclusion Neoadjuvant chemotherapy has a good clinical effect on patients with cervical cancer, combined with timely surgical treatment, tumor resection rate can be significantly increased.